1. Home
  2. GUG vs CRVS Comparison

GUG vs CRVS Comparison

Compare GUG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guggenheim Active Allocation Fund of Beneficial Interest

GUG

Guggenheim Active Allocation Fund of Beneficial Interest

HOLD

Current Price

$15.50

Market Cap

511.2M

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$7.66

Market Cap

634.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GUG
CRVS
Founded
2021
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
511.2M
634.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
GUG
CRVS
Price
$15.50
$7.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$13.75
AVG Volume (30 Days)
108.9K
1.2M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
9.67%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.71
$2.54
52 Week High
$15.06
$9.60

Technical Indicators

Market Signals
Indicator
GUG
CRVS
Relative Strength Index (RSI) 54.14 38.18
Support Level $15.27 $8.31
Resistance Level $15.53 $9.60
Average True Range (ATR) 0.24 0.57
MACD 0.02 -0.16
Stochastic Oscillator 62.01 6.81

Price Performance

Historical Comparison
GUG
CRVS

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: